Frontiers in Nutrition, 7
Allergy 62 (11), 13411342
There are also questions about more serious risks, including blood clot concerns and pancreatic issues, though these remain rare
Conclusion Is BPC-157 Worth the Legal Risk
(1994) The treatment of benzodiazepine dependence
321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or intended to affect the structure or function of the body." FDA's letters to the other manufacturers are similar in their complaints about why their products fall under the agency's regulatory oversight and why the companies are not allowed to market them, despite their oft-cited claims that the products, especially the triple agonists, are for research only